Get the Daily Brief
Latest Biotech News
Proteomics startup Encodia ceases operations and auctions assets
Encodia, a San Diego firm developing DNA‑tagged peptide protein sequencing (ProteoCode), has ceased operations and moved to liquidate laboratory equipment, according to reports and a former...
Cellular Origins, Fresenius Kabi integrate robotic CGT systems – milestone cleared
Cellular Origins and Fresenius Kabi completed the first phase of their collaboration to scale cell and gene therapy manufacturing by integrating Fresenius Kabi’s Cue R cell processing system into...
Macrophage‑targeting CAR T reshapes solid tumor strategy in mice
Researchers at the Icahn School of Medicine at Mount Sinai reported preclinical data showing IL‑12–producing CAR T cells that target tumor‑associated macrophages (TAMs) remodel the tumor...
Genomics pioneer Venter launches Diploid Genomics with seed backing
The J. Craig Venter Institute announced the launch of Diploid Genomics, an AI‑driven genomics analytics spinout co‑founded by J. Craig Venter with seed investment from Healthier Capital. Diploid...
EU launches FAST‑EU pilot: 70‑day ambition to speed multinational trials
The European Union unveiled FAST‑EU, a voluntary pilot intended to accelerate the start‑up timeline for multinational clinical trials with a maximum 70‑day (10‑week) timeline from sponsor...
NVIDIA and Eli Lilly Launch $1B AI Lab — Drug discovery on fast track
NVIDIA and Eli Lilly announced a $1 billion partnership to build an AI-powered drug discovery laboratory aimed at accelerating biologics and small‑molecule discovery. The collaboration will pair...
Bristol Myers Backs Janux — Tumor‑activated T‑cell engager pact valued up to $850M
Bristol Myers Squibb struck a collaboration with Janux Therapeutics to develop tumor‑activated T‑cell engagers, paying $50 million up front and creating up to ~$850 million in potential payments....
Corxel Raises $287M: advancing oral GLP‑1 into global trials
Corxel Pharmaceuticals closed a $287 million Series D to advance its oral GLP‑1 receptor agonist CX‑11 through pivotal development and expand global trials. The financing will support U.S. Phase...
J. Craig Venter Spins Out Diploid Genomics — AI‑driven clinical sequencing analytics
Diploid Genomics launched as a JCVI spinout led by J. Craig Venter, backed by Healthier Capital, to commercialize AI‑driven genomics analytics for research and diagnostics. The company plans to...
Sanofi to file for amlitelimab despite mixed Phase III reads
Sanofi said it will pursue global regulatory submissions for amlitelimab in atopic dermatitis despite mixed Phase III results that produced divergent outcomes under U.S. and EU analyses. One trial...
Moderna pares late‑stage vaccine bets — political backlash reshapes infectious‑disease R&D
Moderna's leadership signaled cuts to investments in late‑stage infectious disease vaccine trials after facing political and public backlash in the U.S. Executives told media the company will...
Erasca closes upsized offering — $258.8M to sharpen RAS oncology push
Erasca closed an upsized public offering that raised approximately $258.8 million to fund its RAS/MAPK pathway oncology programs. The clinical‑stage precision oncology company said all shares were...
Sequencing sector shaken: Guardant remand, Encodia shuts down
Two developments reshaped the sequencing and proteomics landscape: the Federal Circuit remanded Guardant Health’s patent dispute with TwinStrand to the Patent Trial and Appeal Board for further...
EU and UK move to speed trials: FAST‑EU pilot, new UK clinical rules
Regulators in Europe and the U.K. unveiled measures to accelerate multinational trial starts. The EU launched FAST‑EU, a voluntary pilot aiming for a 70‑day timeline from filing to trial start,...
Macrophage‑targeting CAR T reprograms tumor microenvironment — survival gains in mice
Researchers at the Icahn School of Medicine at Mount Sinai reported IL‑12‑producing CAR T cells that directly target tumor‑associated macrophages (TAMs) and reset the immunosuppressive tumor...
Erasca closes upsized stock sale: $258.8M raised
Erasca announced the closing of an upsized public offering, selling 25,875,000 shares at $10.00 each and generating gross proceeds of roughly $258.8 million. The clinical‑stage precision oncology...
Corxel draws $287M — Advances oral GLP‑1 CX‑11
Corxel Pharmaceuticals closed a $287 million Series D round to push its oral small‑molecule GLP‑1 receptor agonist CX‑11 through Phase II and toward global development. The financing will support...
Guardant360 CDx wins FDA nod: Liquid biopsy cleared as companion test
The FDA approved Guardant Health’s Guardant360 CDx as a companion diagnostic to identify BRAF V600E‑mutant metastatic colorectal cancer patients for Pfizer’s encorafenib plus cetuximab and...
NVIDIA, Eli Lilly commit $1B to Bay Area AI lab for drug discovery
NVIDIA and Eli Lilly announced a $1 billion partnership to build an AI‑powered drug discovery laboratory in the San Francisco Bay Area. The collaboration will combine NVIDIA’s computing and AI...
Bristol Myers bets on Janux: $50M upfront for masked T‑cell engagers
Bristol Myers Squibb entered a collaboration with Janux Therapeutics focused on Janux’s tumor‑activated T‑cell engager platform, paying $50 million upfront and leaving the deal worth up to roughly...